SYMPHOGEN A/S AND CAMBRIDGE ANTIBODY TECHNOLOGY SIGN PATENT LICENSING AGREEMENT

Symphogen A/S, a Danish biotechnology company pioneering recombinant human polyclonal antibodies for the treatment and prevention of human disease, announces that it has entered into a patent license agreement with Cambridge Antibody Technology.

Under the terms of the agreement, Symphogen receives a license to use CAT´s antibody phage display patents for research purposes and to develop and commercialize a number of therapeutic and diagnostic antibody products. Upon signing the agreement, Symphogen made an upfront payment for the license and exercised its first product license option to develop and commercialize its lead product Sym001. As a condition of exercising this option, Symphogen paid a product license fee and may make future milestone and royalty payments to CAT.

Sym001 is a recombinant, fully human, anti Rhesus D polyclonal antibody which Symphogen is developing for Idiopathic Thrombocytopenic Purpura (ITP) and Hemolytic Disease of Newborns (HDN). The Company plans to file an INDfor initiation of phase I clinical trials in 2006.

Kirsten Drejer, CEO of Symphogen, commented:

"We are very pleased to have secured access to Cambridge Antibody Technology’s validated phage display patent estate. Combined with our proprietary antibody technology, Symphage™, this strengthens our competitiveness in the antibody arena. This partnership with CAT further supports the clinical development and commercialization of our lead product, Sym001, for the treatment of ITP and HDN. Our strategy is to build a strong portfolio of therapeutic recombinant polyclonal antibodies through our internal efforts and in collaboration with partners.”

Symphogen is a member of Medicon Valley Academy.

More information: www.symphogen.com